Seoul National Univ. DMSE
Notice

Seminar & Colloquium

Seminar & Colloquium
[세미나: 6월 19일(월), 오후 5시] Prof. Kyung Soo Park, Harvard University

[세미나: 6월 19일(월), 오후 4시] Prof. Kyung Soo Park, Harvard  University

 

Title

Bone Marrow-derived Macrophages as a Potent Immune Initiator against Cancer.

 

Speaker

Prof. Kyung Soo Park, School of Engineering and Applied Sciences, Harvard University

 

EDUCATION

- 2006 ~ 2012 B.S., Chemical and Biomolecular Engineering, Sogang University, S Korea

- 2012 ~ 2014 M.S., Chemical and Biomolecular Engineering, Sogang University, S Korea

- 2015 ~ 2020 Ph.D., Biomedical Engineering, University of Michigan, Ann Arbor, Michigan

 

RESEARCH EXPERIENCE

- 2014 ~ 2015 Researcher,  Advanced  Bio-inspired  Materials  &  Immunoengineering  Laboratory, Sungkyunkwan 

University, S Korea

- 2015. 01 ~ 2015. 05. Visiting student, Disease Biophysics Group, School of Engineering and Applied Sciences, Harvard 

University, Cambridge, Massachusetts

- 2020 ~ 2021 Postdoctoral fellow, Pharmaceutical Sciences, University of Michigan, Ann Arbor, Michigan

- 2021 ~ present Postdoctoral  fellow,  School  of  Engineering  and  Applied  Sciences,  Harvard  University,  Allston, 

Massachusetts

 

| Date | Monday, June 19th, 2023

| Time | 17:00 ~ 

| Venue | 신소재공동연구소(131동) 1층 세미나실(제1세미나실)

 

[Abstract]

Macrophages  are  one  of  the  important  immune  cell  types  in  cancer  biology.  Despite  their abundance and ubiquitous presence in inflamed and infected tissues, macrophages have been largely neglected for their role in antigen presentation in part due to the perception that their key function is in innate immunity and that they are less efficient in antigen presentation compared to dendritic cells. However, being a professional antigen-presenting cell and an efficient phagocyte with a unique in vivo trafficking behavior, macrophages, upon engineering, have great potential to induce  potent  and  multi-faceted  immune  responses  against  cancer.  Macrophages  that  are differentiated from peripheral monocytes or bone-marrow cells through in vitro cultures have been leveraged  to  exert  various  functionalities  upon  in  vivo  administration  depending  on  the pathological context. There are reports of macrophage usage in many applications, ranging from cancer diagnosis to therapeutics. Here, we investigated the potential of bone marrow-derived macrophages as a cell therapy against cancer, by demonstrating their use as a cell-based vaccine. Owing to their unique ability to infiltrate tissues, macrophages show a unique in vivo trafficking behavior and orchestrate the modulation of multiple stages of immune responses, providing a new platform for cancer vaccines that could be effective against tumors that have been less responsive to traditional cancer vaccines.

 

| Host | 도준상 교수 (02-880-1605)